A Novel And Potent Tumor Cell Autosis Technique

Studies are ongoing at Houston Methodist on a novel and promising technique using CAR T cells infected with an oncolytic virus that delivers a 100% kill rate of solid tumors.

Taking Neurology to New Frontiers

Jun Li, MD, PhD, the new chair of the Stanley H. Appel Department of Neurology answered a few questions about his career trajectory and his vision for the department.

A Therapeutic Target for Multiple Myeloma-Related Bone Disease

Integrin α6 is a Novel Potential Therapeutic Target for Multiple Myeloma-Associated Osteolytic Lesions

Infertility Reversed by Reducing Blood Cholesterol

Serum Opacity Factor Reverses Female Infertility by Reducing HDL Cholesterol

In Pursuit of Biomarkers for Diseases of the Mind

Researchers at Houston Methodist turn toward the gut microbiome for biomarkers predictive of the severity of anxiety and depression.

An Innovative New Approach to Managing Liver Cancers

The Combination of Sorafenib with Transarterial Chemoembolization Improved Overall Survival In Liver Transplant Patients With Unresectable Malignancies

Maximizing cancer immunotherapy success rates – a look into the future

An app on the horizon for predicting cancer immunotherapy success rates tailored for each patient

First Biomarkers Identified to Measure ALS Disease Progression and Therapeutic Response

The biomarkers have the potential to track amyotrophic lateral sclerosis progression and assess the efficacy of novel treatments.

Designer Nanoparticles Deliver Drug to Dial Down Inflammation

New nanoparticles can be guided to go to site of spinal cord injury and reduce inflammation.

Houston Methodist Team Carves a NICHE in State-of-the-Art Diabetes Therapy

Researchers Awarded R01 for Further Study of Subcutaneous Device for Management of Type 1 Diabetes

A Potential Strategy to Enhance Multiple Myeloma Therapeutic Efficacy

Houston Methodist researchers identified previously unknown mechanistic details in the pathogenesis of MM and therapeutic resistance which can be leveraged for future therapies.

Theranostic Modulations Push the Cancer-Treatment Envelope

Intratumoral distribution and retention of theranostic particles can be improved by controlling protein adsorption to advance cancer management

New Hope for Sleep Apnea Patients May Be Coming

The cardiac autonomic nervous system is a potential therapeutic target for atrial fibrillation

The NanoLymph: Implantable. Adaptable. Anti-Cancer.

The Implantable Nanolymph Cancer Vaccine Device Can Locally Recruit and Activate Antitumor Immune Cells to Elicit a Systemic Antitumor Immune Response.

COVID-19 Infection in Crucial Brain Regions May Lead To Accelerated Brain Aging

The disease may put vulnerable individuals at risk for irreversible neurological conditions.

Researchers Uncover Distinct Patterns of a Common Pathology in Dementia

Known as LATE, a very common form of brain pathology affects ~40% of elderly patients. Researchers at Houston Methodist have unraveled several patterns of LATE in the brains of aging and demented patients. These patterns have distinct clinical, pathologic and genetic associations.

Deepening Insights into Human Brain Disease

Houston Methodist’s neural biorepository or NBRX is a core facility of the Department of Neurosurgery. It provides patient-derived tissue samples to facilitate translational and basic neuroscience research across the Texas Medical Center.

Is there hope for an FDA-approved therapy specifically for PAD?

Current Peripheral Arterial Disease therapies offer relief from symptoms, but novel therapeutics are urgently needed

Researchers identify a novel immunotherapy target to combat glioblastomas

Houston Methodist researchers have used advanced microfluidic technology to fingerprint different types of cells in glioblastoma. Their analysis has revealed a protein that could serve as a potential immunotherapy target for one of the deadliest cancers.

Inspired by our own cells, biomimetic nano-carrier platforms may one day improve the safety and efficacy of cardiovascular disease medications by improving interactions with target cells and extending circulation times.